meRfi®-GM
Clostridioides difficile infection (CDI)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Clostridioides difficile (CDI) intestinal infections are among the most common nosocomial infections in high-income countries
Clostridioides difficile infection (CDI) is a common infection acquired in hospitals in the USA. It affects 500,000 people each year and results in healthcare costs that surpass $1.5 billion.
CDC 2022 Educational resources (Centers for Disease Control and Prevention). https://www.cdc.gov/cdiff/materials.html.
Enterococci enhance the fitness and pathogenesis of Clostridioides difficile in the gut by altering the amino acid composition and providing signals that increase its virulence towards the host
Clostr…
References (Sources)
- Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota
- Clostridium difficile infection in the community: a zoonotic disease?
- Clostridium difficile infection: new developments in epidemiology and pathogenesis
- Enterococci enhance Clostridioides difficile pathogenesis
- Innate Lymphoid Cells: Important Regulators of Host-Bacteria Interaction for Border DefenseReview
- Microbiota-based markers predictive of development of Clostridioides difficile infection
- Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection